Navigation Links
Model-Based Drug Development 101, a new Xtalks webinar
Date:2/6/2013

Toronto, Canada (PRWEB) February 06, 2013

As the development of new drugs is becomes increasingly expensive and lengthy process, it’s clear that new approaches must be explored.

With model-based drug development (MBDD), mathematical models can be used early on to test extremely complex situations before deciding on a course of action. These models can identify the right dose, the right population, optimize clinical protocol, program, and portfolio designs, and compare candidates with existing drugs — ultimately providing better decisions and optimized returns.

Expert speakers will provide an overview of the basics of model based drug development and its practical applications — from electing the right dose and population to optimizing trial, program, and portfolio design.

Attendees will get a sense of how model- based drug development can help to:

  •     Improve communication across disciplines
  •     Utilize the many data domains to improve drug development
  •     Make better, quantitative, data-driven decisions

A live Q&A with the audience will follow the main presentation.

For more information about this event or to register, http://xtks.in/xto569-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10386010.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
3. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
6. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
7. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
8. Idenix Reports Advancement of HCV Development Pipeline
9. Almost perfect: A breakthrough in superlens development
10. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
11. New Software from SRI Speeds Development of Genome-Scale Models for Drug and Fuel Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):